An expert MD reveals clear insights into cataract surgery, spotlighting the breakthroughs in treatment: "We live in a time of ...
A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...
A small carefully constructed and blinded clinical trial confirms that percutaneous intervention significantly relieves angina in patients with chronic total obstruction.
Positive topline results from the phase 3 GLOW2 trial suggest that tarcocimab tedromer (Zenkuda), an investigational anti–vascular endothelial growth factor (VEGF) biologic, may offer durable disease ...
In a phase 2 trial, OCU410, a modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, ...